Human Reproduction, Vol 12, 1293-1297, Copyright © 1997 by Oxford University Press
KG Danielsson, ML Swahn and M Bygdeman
Leukaemia inhibitory factor (LIF) is a cytokine which plays an obligatory
role in mouse blastocyst implantation. In human endometrium, LIF expression
is significantly increased in the mid-luteal phase indicating that LIF may
also play an important role in the human. We have previously shown that a
single dose of 200 mg of mifepristone immediately post-ovulation is an
effective contraceptive method, probably due to inhibition of endometrial
development and function. The purpose of this study was to investigate the
effect of various doses of mifepristone on endometrial LIF expression. A
total of 22 fertile, regularly-menstruating women were studied during
control and treatment cycles. The subjects were divided into four groups:
group I received a single dose of 200 mg of mifepristone on cycle day LH +
2 (n = 7). The subjects in groups II and III were treated with either 5 mg
(n = 5) or 2.5 mg (n = 5) once a week for 2 months. Group IV subjects
received 0.5 mg per day (n = 5) of mifepristone for 3 months. LIF was
measured immunohistochemically in endometrial tissue specimens taken on the
corresponding day (cycle day LH + 6 to LH + 8) in hormonally- characterized
control and treatment cycles. LIF immunostaining was observed in all
controls and located to the cytoplasm of the luminal and glandular
epithelial cells and stromal cells. In the treatment cycles the staining of
luminal epithelium and stroma was similar to controls, while the glandular
staining was reduced in all treatment groups. This study reveals that early
luteal phase treatment as well as intermittent or daily low dose treatment
with mifepristone reduces endometrial glandular LIF expression at the
expected time of implantation. The results further support the
contraceptive potential of mifepristone in low doses.
ARTICLES
The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase--an immunohistochemical study
Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Nelson and I. A. Greer The potential role of heparin in assisted conception Hum. Reprod. Update, November 1, 2008; 14(6): 623 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wanggren, P.G. Lalitkumar, F. Hambiliki, B. Stabi, K. Gemzell-Danielsson, and A. Stavreus-Evers Leukaemia inhibitory factor receptor and gp130 in the human Fallopian tube and endometrium before and after mifepristone treatment and in the human preimplantation embryo Mol. Hum. Reprod., June 1, 2007; 13(6): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Achache and A. Revel Endometrial receptivity markers, the journey to successful embryo implantation Hum. Reprod. Update, November 1, 2006; 12(6): 731 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dimitriadis, C.A. White, R.L. Jones, and L.A. Salamonsen Cytokines, chemokines and growth factors in endometrium related to implantation Hum. Reprod. Update, November 1, 2005; 11(6): 613 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gemzell-Danielsson and L. Marions Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348. [Abstract] [Full Text] [PDF]
|
|